Education
About Us
Working with TipRanks
Follow Us
Azitra Inc (AZTR)
:AZTR
Top Page
Azitra Inc
(NYSE MKT:AZTR)
46Neutral
Positive Factors
Clinical Trials
The ATR-12 program in Netherton syndrome has dosed the first patient in its P1b study, with initial data expected soon.
Regulatory Progress
The ATR-04 program in EGFRi-associated rash has received IND clearance, and there are plans to initiate a P1/2 study.
Negative Factors
Stock Valuation
Azitra's valuation has retreated to near a 52-week low due to a lack of catalysts and cash needs.
Azitra Inc (AZTR) vs. S&P 500 (SPY)
Market Cap
N/A
Dividend YieldN/A
Average Volume (3M)11.35M
Price to Earnings (P/E)―
Beta (1Y)2.00
Revenue Growth-98.91%
EPS Growth75.80%
CountryUS
Employees10
SectorHealthcare
Sector Strength78
IndustryBiotechnology
Share Statistics
EPS (TTM)-7.59
Shares Outstanding14,979,354
10 Day Avg. Volume365,869
30 Day Avg. Volume11,348,367
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)685.85
Price to Cash Flow (P/CF)-0.50
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$3.00Price Target Upside782.35% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Azitra Inc Business Overview & Revenue Model
Company DescriptionAzitra Inc (AZTR) is a biotechnology company specializing in the development of microbiome-based therapeutics for dermatological conditions. The company operates within the biotechnology and healthcare sectors, focusing on leveraging its proprietary technology platform to create innovative treatments for skin diseases. Azitra's core products aim to address conditions such as eczema, acne, and other skin-related disorders by utilizing genetically engineered microbes to enhance skin health and treat underlying causes of dermal diseases.
How the Company Makes MoneyAzitra Inc makes money primarily through the development and commercialization of its microbiome-based therapeutic products. The company generates revenue through partnerships and licensing agreements with pharmaceutical firms interested in integrating its innovative solutions into their product lines. Additionally, Azitra may receive funding and grants from governmental and non-governmental organizations supporting biotech research. The company might also explore revenue streams through the direct sale of its developed products once they receive regulatory approvals. Strategic collaborations with healthcare providers and research institutions also play a significant role in its revenue model, facilitating the advancement and potential monetization of its therapeutic pipeline.
Azitra Inc Financial Statement Overview
Summary
Azitra Inc demonstrates significant revenue growth, which is a positive sign for future potential. However, persistent high losses and negative cash flows indicate underlying operational inefficiencies and financial vulnerabilities. The balance sheet reflects improved equity but high liabilities and substantial cash burn remain critical challenges.Income Statement
Azitra Inc reported significant revenue growth from $686,000 in 2023 to $7,500,000 in 2024, indicating a positive trajectory in revenue generation. However, the company suffers from extremely high net and operating losses, demonstrated by negative EBIT and EBITDA figures. The net profit margin remains negative due to substantial operational expenses surpassing revenue gains.35
Negative
Balance Sheet
The balance sheet shows a strong equity position with stockholders' equity of $5,698,298,000 in 2024, reflecting a positive turnaround from negative equity in previous years. The debt-to-equity ratio is low, indicating prudent financial leverage. However, considerable liabilities could pose risks if revenue growth does not continue.45
Neutral
Cash Flow
Negative operating cash flows of -$10,183,740,000 in 2024 highlight cash constraints, limiting operational flexibility. Free cash flow remains deeply negative, though slight improvement is seen from the previous period. The lack of positive cash flows raises concerns about the company's ability to fund operations without external financing.30
Negative
| Breakdown | |||
| Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|
| Income Statement | Total Revenue | ||
| 7.50M | 686.00K | 284.00K | 110.00K | Gross Profit |
| 7.50M | 260.45K | -121.98K | 25.23K | EBIT |
| -10.99B | -7.62M | -9.45M | -9.22M | EBITDA |
| -10.99B | -10.67M | -10.02M | -8.79M | Net Income Common Stockholders |
| -8.97M | -11.28M | -10.68M | -8.94M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||
| 4.55B | 1.80M | 3.49M | 8.04M | Total Assets |
| 7.36B | 5.12M | 7.17M | 10.20M | Total Debt |
| 555.51M | 885.95K | 7.73M | 992.02K | Net Debt |
| -4.00B | -910.04K | 4.24M | -7.05M | Total Liabilities |
| 1.66B | 2.20M | 43.43M | 35.97M | Stockholders Equity |
| 5.70B | 2.91M | -36.26M | -25.77M |
| Cash Flow | Free Cash Flow | ||
| -10.19B | -7.68M | -8.51M | -8.52M | Operating Cash Flow |
| -10.18B | -7.36M | -8.35M | -8.07M | Investing Cash Flow |
| -379.25M | -318.26K | -336.76K | -652.27K | Financing Cash Flow |
| 13.32M | 5.98M | 4.13M | 992.86K |
Azitra Inc Technical Analysis
Negative
0.34
Price Trends
0.35
Negative
0.42
Negative
1.21
Negative
Market Momentum
>-0.01
Positive
48.05
Neutral
51.14
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AZTR, the sentiment is Negative. The current price of 0.34 is below the 20-day moving average (MA) of 0.36, below the 50-day MA of 0.35, and below the 200-day MA of 1.21, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 48.05 is Neutral, neither overbought nor oversold. The STOCH value of 51.14 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AZTR.
Azitra Inc Risk Analysis
Azitra Inc disclosed 43 risk factors in its most recent earnings report. Azitra Inc reported the most risks in the “Finance & Corporate” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Azitra Inc Peers Comparison
Overall Rating
UnderperformOutperform
Sector (49)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
77 Outperform | $5.33B | 61.87 | 10.34% | ― | 473.02% | 1620.44% | |
49 Neutral | $6.90B | 0.01 | -53.76% | 2.46% | 24.91% | -3.11% | |
48 Neutral | $47.76M | ― | -256.45% | ― | -22.81% | 86.68% | |
46 Neutral | ― | -208.27% | ― | -98.91% | 75.80% | ||
44 Neutral | $36.51M | ― | -137.40% | ― | ― | 37.42% | |
39 Underperform | $107.58M | ― | -129.58% | ― | -27.69% | -27.91% |
* Healthcare Sector Average
Performance Comparison
AZTR
Azitra Inc
0.34
-6.71
-95.18%
FBIO
Fortress Biotech
1.73
-0.09
-4.95%
FBRX
Forte Biosciences
5.82
-10.38
-64.07%
KRYS
Krystal Biotech
178.39
-0.96
-0.54%
DERM
Journey Medical Corp
5.31
1.90
55.72%
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.